


```
=> e piperidine/cn
E1          1      PIPERIDINAMINE, N-((3,4-DIMETHOXYPHENYL)METHYL)-/CN
E2          1      PIPERIDINAMINE, POLYMER WITH (CHLOROMETHYL)OXIRANE AND 4,4'-(1-METHYLETHYLIDENE)BIS(PHENOL)/CN
E3          1 --> PIPERIDINE/CN
E4          1      PIPERIDINE 1,2-CYCLOBUTANE DICARBOXYLATE/CN
E5          1      PIPERIDINE 1,2-CYCLOHEXANEDICARBOXYLATE/CN
E6          1      PIPERIDINE 1,2-CYCLOPENTANE DICARBOXYLATE/CN
E7          1      PIPERIDINE 1,2-CYCLOPROPANE DICARBOXYLATE/CN
E8          1      PIPERIDINE 183A/CN
E9          1      PIPERIDINE 2,4,6-TRINITROPHENOLATE/CN
E10         1      PIPERIDINE 2,4-DINITROPHENOLATE/CN
E11         1      PIPERIDINE 207E/CN
E12         1      PIPERIDINE 211B/CN
```

```
=> s e3
L1          1 PIPERIDINE/CN
```

```
=> d str rsd
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
```



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C5N	NC5	6	C5N	46.156.1	1

```
=> e indole/cn
E1          1      INDOLAPRILAT/CN
E2          1      INDOLBI/CN
E3          1 --> INDOLE/CN
E4          1      INDOLE 2,3-DIOXYGENASE/CN
E5          1      INDOLE 3-ACETONITRILASE/CN
E6          1      INDOLE 3-ACETYLASPARTATE HYDROLYASE/CN
E7          1      INDOLE 3-HYDROXYLASE/CN
E8          1      INDOLE ACETAMIDE HYDROLASE (AGROBACTERIUM TUMEFACIENS STRAIN C58 GENE TMS2)/CN
E9          1      INDOLE ACETAMIDE HYDROLASE (AZOARCUS STRAIN BH72 GENE TMS)/CN
E10         1      INDOLE ACETAMIDE HYDROLASE (BRADYRHIZOBIUM JAPONICUM STRAIN USDA110 GENE TMS2)/CN
E11         1      INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA PSEUDOMALLEI STRAIN K96243)/CN
E12         1      INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA XENOVORANS STRAIN L
```


B400)/CN

=> s e3

L2 1 INDOLE/CN

=> d str rsd

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C4N-C6	NC4-C6	5-6	C8N	333.151.57	1


FILE 'REGISTRY' ENTERED AT 07:16:00 ON 28 MAY 2009

 E PIPERIDINE/CN
L1 1 S E3
 E INDOLE/CN
L2 1 S E3
L3 210333 S 46.156/RID (P) 333.151/RID
L4 STRUC
L5 18 SEARCH L4 SSS SUB=L3 SAMPLE

=> d 14

L4 HAS NO ANSWERS

L4 STR



VAR G1=8/7/12/11

VPA 16-1/2/3 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 7 3

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:13

'L3' IS NOT A VALID SEARCH SCOPE

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:end

SEARCH ENDED BY USER

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):13

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful

FULL SUBSET SEARCH INITIATED 07:24:35 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 207321 TO ITERATE

100.0% PROCESSED 207321 ITERATIONS

3811 ANSWERS

SEARCH TIME: 00.00.05

L6 3811 SEA SUB=L3 SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

217.04

217.26

FILE 'CAPLUS' ENTERED AT 07:24:46 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009 (20090527/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

=> s 16

L7 169 L6

=> s 17 and 5ht?

9349 5HT?

L8 8 L7 AND 5HT?

=> d bib hitstr 8

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1998:682229 CAPLUS

DN 129:302552

OREF 129:61715a,61718a

TI Preparation of 1,4-disubstituted cyclic amine derivatives as serotonin antagonists

IN Kitazawa, Noritaka; Ueno, Kohshi; Takahashi, Keiko; Kimura, Teiji; Sasaki, Atsushi; Kawano, Koki; Okabe, Tadashi; Komatsu, Makoto; Matsunaga, Manabu; Kubota, Atsuhiko

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 635 pp.
CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9843956	A1	19981008	WO 1998-JP1481	19980331
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 242011	B	20051021	TW 1998-87104733	19980330
	CA 2280753	A1	19981008	CA 1998-2280753	19980331

CA	2280753	C	20071204		
AU	9865209	A	19981022	AU 1998-65209	19980331
AU	748038	B2	20020530		
ZA	9802707	A	19991020	ZA 1998-2707	19980331
EP	976732	A1	20000202	EP 1998-911137	19980331
EP	976732	B1	20041124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
HU	2000000434	A2	20000628	HU 2000-434	19980331
HU	2000000434	A3	20020528		
NZ	337651	A	20020426	NZ 1998-337651	19980331
RU	2203275	C2	20030427	RU 1999-123039	19980331
AT	283259	T	20041215	AT 1998-911137	19980331
ES	2230681	T3	20050501	ES 1998-911137	19980331
CN	1204121	C	20050601	CN 1998-803861	19980331
JP	3953115	B1	20070808	JP 1998-541460	19980331
US	6448243	B1	20020910	US 1999-367227	19990811
NO	9904720	A	19991130	NO 1999-4720	19990928
NO	314543	B1	20030407		
HK	1026700	A1	20050826	HK 2000-105871	20000919
US	20020086999	A1	20020704	US 2001-846259	20010502
US	7071201	B2	20060704		
US	20020019531	A1	20020214	US 2001-859517	20010518
US	6579881	B2	20030617		
PRAI	JP 1997-98433	A	19970331		
	JP 1997-366764	A	19971226		
	WO 1998-JP1481	W	19980331		
	US 1999-367227	A3	19990811		
OS	MARPAT 129:302552				
IT	214611-86-6P 214611-87-7P 214611-88-8P				
	214611-89-9P 214616-51-0P 214616-52-1P				
	214616-53-2P 214616-54-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 1,4-disubstituted cyclic amine derivs. as serotonin antagonists)				
RN	214611-86-6 CAPLUS				
CN	1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)- (CA INDEX NAME)				




RN 214611-87-7 CAPLUS

CN Ethanone, 1-[4-[[1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-indol-6-yl]methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 214611-88-8 CAPLUS

CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 214611-89-9 CAPLUS

CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]- (CA INDEX NAME)



RN 214616-51-0 CAPLUS


CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 214616-52-1 CAPLUS

CN Ethanone, 1-[4-[[1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-indol-6-yl]methyl]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 214616-53-2 CAPLUS


CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-, monohydrochloride (9CI)

(CA INDEX NAME)



● HCl

RN 214616-54-3 CAPLUS
CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 7


L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:832788 CAPLUS
DN 137:337885
TI Preparation of heterocyclyloxy-, heterocyclylthioxy- and
heterocyclylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands
IN Zhou, Ping; Harrison, Boyd Lynn; Li, Yanfang
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002085892	A1	20021031	WO 2002-US12415	20020419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2444095 A1 20021031 CA 2002-2444095 20020419
 AU 2002307424 A1 20021105 AU 2002-307424 20020419
 US 20030069278 A1 20030410 US 2002-126598 20020419
 US 6815456 B2 20041109
 EP 1385842 A1 20040204 EP 2002-764248 20020419
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 HU 2003003958 A2 20040428 HU 2003-3958 20020419
 CN 1518547 A 20040804 CN 2002-812308 20020419
 CN 1293072 C 20070103
 BR 2002009056 A 20040810 BR 2002-9056 20020419
 JP 2004526787 T 20040902 JP 2002-583419 20020419
 IN 2003KN01264 A 20060310 IN 2003-KN1264 20031006
 MX 2003009476 A 20040212 MX 2003-9476 20031016
 NO 2003004648 A 20031120 NO 2003-4648 20031017
 ZA 2003009004 A 20050221 ZA 2003-9004 20031119
 US 20050065186 A1 20050324 US 2004-949062 20040924
 AU 2008203389 A1 20080821 AU 2008-203389 20080729
 PRAI US 2001-285643P P 20010420
 AU 2002-307424 A3 20020419
 US 2002-126598 A3 20020419
 WO 2002-US12415 W 20020419
 OS MARPAT 137:337885
 IT 474002-60-3P 474002-62-5P 474003-38-8P
 474003-40-2P 474003-42-4P 474003-44-6P
 474003-46-8P 474003-48-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of heterocyclyloxy-, heterocyclylthioxy- and
 heterocyclylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands)
 RN 474002-60-3 CAPLUS
 CN Benzenamine, 4-[[4-(4-piperidinyloxy)-1H-indol-1-yl]sulfonyl]-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 474002-62-5 CAPLUS
 CN Benzenamine, 4-[[4-(3-piperidinyloxy)-1H-indol-1-yl]sulfonyl]-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 474003-38-8 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)



RN 474003-40-2 CAPLUS
 CN Benzenamine, 4-[[4-(3-piperidinyloxy)-1H-indol-1-yl]sulfonyl]- (CA INDEX NAME)




RN 474003-42-4 CAPLUS
 CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)




RN 474003-44-6 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)




RN 474003-46-8 CAPLUS

CN Benzenamine, 4-[[4-(4-piperidinyloxy)-1H-indol-1-yl]sulfonyl]- (CA INDEX NAME)



RN 474003-48-0 CAPLUS

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 6


L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:656767 CAPLUS
DN 139:197493
TI Preparation of heterocyclic compounds possessing affinity at 5-HT₁-type
receptors and uses thereof in therapy
IN Harrington, Frank Peter; Smith, Paul William; Ward, Simon E.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068772	A1	20030821	WO 2003-EP1711	20030217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003212254	A1	20030904	AU 2003-212254	20030217
	EP 1476444	A1	20041117	EP 2003-708113	20030217
	EP 1476444	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527500	T	20050915	JP 2003-567899	20030217
	AT 323085	T	20060415	AT 2003-708113	20030217
	ES 2259759	T3	20061016	ES 2003-708113	20030217
	US 20050085458	A1	20050421	US 2004-504109	20040810
	US 7244726	B2	20070717		
PRAI	GB 2002-3804	A	20020218		
	WO 2003-EP1711	W	20030217		
OS	MARPAT 139:197493				
IT	583031-40-7P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic				

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinyll/piperazinyllalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-40-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinylidene]methyl]- (CA INDEX NAME)




IT 583031-41-8P, 6-[1-[2-((2-Methylquinolin-5-yl)oxy)ethyl]piperidin-4-ylmethyl]-1,3-dihydroindol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperidinyll/piperazinyllalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-41-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 583031-25-8P, 6-(Piperidin-4-ylidenemethyl)-1,3-dihydroindol-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of piperidinyll/piperazinyllalkyl substituted benzoxazines as
 ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)
 RN 583031-25-8 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-6-(4-piperidinyllidenemethyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 5

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:490721 CAPLUS
 DN 141:54192
 TI Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular
 selective 5-HT6 antagonists, for treating CNS disorders
 IN Zhao, Shu-Hai
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050085	A1	20040617	WO 2003-EP13372	20031127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,	
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,	
	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,	
	TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,	
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,	
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,	
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	

CA	2508315	A1	20040617	CA	2003-2508315	20031127
AU	2003289903	A1	20040623	AU	2003-289903	20031127
AU	2003289903	B2	20080626			
EP	1569638	A1	20050907	EP	2003-782240	20031127
EP	1569638	B1	20070905			

R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR	2003016962	A	20051025	BR	2003-16962	20031127
CN	1713908	A	20051228	CN	2003-80104019	20031127
JP	2006509777	T	20060323	JP	2004-556206	20031127
NZ	539950	A	20070531	NZ	2003-539950	20031127
TW	284124	B	20070721	TW	2003-92133339	20031127
AT	372113	T	20070915	AT	2003-782240	20031127
ES	2291722	T3	20080301	ES	2003-782240	20031127
RU	2350602	C2	20090327	RU	2005-121125	20031127
US	20040132799	A1	20040708	US	2003-724683	20031201
US	7084169	B2	20060801			
ZA	2005004412	A	20060426	ZA	2005-4412	20050530
MX	2005005790	A	20051018	MX	2005-5790	20050531
IN	2005CN01106	A	20070720	IN	2005-CN1106	20050602
KR	755580	B1	20070906	KR	2005-710127	20050603


PRAI	US	2002-430506P	P	20021203
	WO	2003-EP13372	W	20031127

OS	MARPAT	141:54192
----	--------	-----------

IT	706783-81-5P, 3-Benzenesulfonyl-7-(piperidin-4-yloxy)-1H-indole
	monohydrochloride 706784-50-1P,
	3-Benzenesulfonyl-7-(piperidin-4-yloxy)-1H-indole
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU
	(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
	(Uses)
	(5-HT6 antagonist; preparation of aminoalkoxyindoles as 5-HT6-receptor
	ligands, in particular selective 5-HT6 antagonists, for treating CNS
	disorders)

RN	706783-81-5	CAPLUS
----	-------------	--------


CN	1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)-, hydrochloride (1:1)
	(CA INDEX NAME)



● HCl

RN 706784-50-1 CAPLUS

CN 1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)- (CA INDEX NAME)




IT 706784-12-5P, 4-[[3-(Benzenesulfanyl)-1H-indol-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 706784-15-8P, 4-[[3-(Benzenesulfonyl)-1H-indol-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)

RN 706784-12-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(phenylthio)-1H-indol-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 706784-15-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-,
 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 4

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:979638 CAPLUS
 DN 143:286283
 TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
 IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 102004010132 A1 20050915 DE 2004-102004010132 20040227
AU 2005217043 A1 20050909 AU 2005-217043 20050214
CA 2557489 A1 20050909 CA 2005-2557489 20050214
EP 1718634 A1 20061108 EP 2005-715322 20050214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

JP 2007523930 T 20070823 JP 2007-500098 20050214
US 20070197596 A1 20070823 US 2006-590912 20060828

PRAI DE 2004-102004010132 A 20040227
WO 2005-EP1446 W 20050214


OS MARPAT 143:286283

IT 1066560-13-1 1066560-14-2 1066560-15-3
1066560-16-4 1066560-17-5 1066560-18-6
1066560-19-7 1066560-20-0 1066560-21-1
1066560-22-2 1066560-23-3 1066560-24-4
1066560-25-5 1066560-26-6 1066560-27-7
1066560-28-8 1066560-29-9 1066560-30-2
1066560-31-3 1066560-32-4 1066560-33-5
1066560-34-6

RL: PRPH (Prophetic)
(Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)


RN 1066560-13-1 CAPLUS

CN Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-14-2 CAPLUS

CN Cyanic acid, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-15-3 CAPLUS

CN Benzonitrile, 4-[2-[4-[amino(3-fluoro-2,3-dihydro-1H-indol-7-yl)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 1066560-16-4 CAPLUS

CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-17-5 CAPLUS


CN Cyanic acid, 7-[[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl](dimethylamino)methyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-18-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-19-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-20-0 CAPLUS
CN Benzonitrile, 4-[2-[4-[[2,3-dihydro-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl](dimethylamino)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1066560-21-1 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 1066560-22-2 CAPLUS

CN 1H-Indole-7-methanamine, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)




RN 1066560-23-3 CAPLUS

CN Cyanic acid, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-24-4 CAPLUS

CN Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-25-5 CAPLUS


CN Benzonitrile, 4-[2-[4-[(3-fluoro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 1066560-26-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1066560-27-7 CAPLUS
 CN Cyanic acid, 7-[[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl] ester (CA INDEX NAME)




RN 1066560-28-8 CAPLUS
 CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl](dimethylamino)methyl]-1H-indol-3-yl ester (CA INDEX NAME)




RN 1066560-29-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-30-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 1066560-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A




RN 1066560-32-4 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 1066560-33-5 CAPLUS

CN 1H-Indole-7-methanamine, 3-fluoro- α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)




RN 1066560-34-6 CAPLUS


CN Benzonitrile, 4-[2-[4-[(3-fluoro-2,3-dihydro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)




IT 864297-53-0P 864297-54-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT_{2a} antagonists)
 RN 864297-53-0 CAPLUS
 CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-
 (CA INDEX NAME)



RN 864297-54-1 CAPLUS
 CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)




IT 864297-55-2P 864297-56-3P 864297-57-4P
 864297-58-5P 864297-59-6P 864297-60-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT_{2a} antagonists)
 RN 864297-55-2 CAPLUS
 CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-
 piperidinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864297-56-3 CAPLUS
 CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-


2,3-dihydro- (CA INDEX NAME)




RN 864297-57-4 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[[7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl]-2,2,2-trifluoroethyl]-4-piperidinyl]ethanone (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 864297-58-5 CAPLUS
CN Ethanone, 1-[7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 864297-59-6 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]- (CA INDEX NAME)




RN 864297-60-9 CAPLUS
 CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]- (CA INDEX NAME)



IT 864297-61-0 864297-62-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)
 RN 864297-61-0 CAPLUS
 CN 1H-Indole-7-methanol, α -4-piperidinyl- (CA INDEX NAME)




RN 864297-62-1 CAPLUS
 CN 1H-Indole-7-methanol, 2,3-dihydro-α-4-piperidinyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib hitstr 3

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:198079 CAPLUS
 DN 144:362583
 TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly
 selective 5-HT2A antagonists
 AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf;
 Ackermann, Karl-August; van Amsterdam, Christoph
 CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
 SO ChemMedChem (2006), 1(2), 245-255
 CODEN: CHEMGX; ISSN: 1860-7179
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 IT 864297-53-0 864297-54-1 864297-56-3
 864297-57-4 864297-59-6 864297-60-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and structure activity relations of
 (phenethylpiperidinyl)phenylethanols as potent and highly selective
 5-HT2A antagonists)
 RN 864297-53-0 CAPLUS
 CN 1H-Indole-7-methanol, α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-
 (CA INDEX NAME)




RN 864297-54-1 CAPLUS

CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)




RN 864297-56-3 CAPLUS


CN 1H-Indole-7-methanol, α -[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 864297-57-4 CAPLUS
 CN Ethanone, 2,2,2-trifluoro-1-[7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl]- (CA INDEX NAME)


PAGE 1-A






RN 864297-59-6 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]- (CA INDEX NAME)




RN 864297-60-9 CAPLUS

CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]- (CA INDEX NAME)



IT 864297-62-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and structure activity relations of
 (phenethylpiperidinyl)phenylethanols as potent and highly selective
 5-HT_{2A} antagonists)
 RN 864297-62-1 CAPLUS
 CN 1H-Indole-7-methanol, 2,3-dihydro- α -4-piperidinyl- (CA INDEX NAME)




RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 2

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:1356517 CAPLUS
 DN 148:92237
 TI New Serotonin 5-HT₆ Ligands from Common Feature Pharmacophore Hypotheses
 AU Kim, Hye-Jung; Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo;
 No, Kyoung Tai; Park, Woo-Kyu; Pae, Ae Nim
 CS Life Science Division, Korea Institute of Science and Technology, Seoul,
 130-650, S. Korea

SO Journal of Chemical Information and Modeling (2008), 48(1), 197-206
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English
 IT 1000170-74-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug design, structure-activity profile and a sequential virtual screening procedure for new serotonin 5-HT6 ligands from common feature pharmacophore hypotheses)
 RN 1000170-74-0 CAPLUS
 CN Benzenesulfonamide, N-[7-[[[(2R,4S)-2-fluoro-4-piperidinyl]methyl]-1H-indol-5-yl]-2-methoxy-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 1

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:336963 CAPLUS
 DN 150:329617
 TI Substituted indolyl compounds as 5-HT6 ligands and their preparation, and use in the treatment of diseases
 IN Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati, Rama Sastri; Jasti, Venkateswarlu
 PA Suven Life Sciences Limited, India
 SO PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009034581	A1	20090319	WO 2008-IN280	20080502
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,			

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI IN 2007-CH2030 A 20070911

OS MARPAT 150:329617


IT 1131452-43-1P 1131452-44-2P 1131452-45-3P
 1131452-46-4P 1131452-47-5P 1131452-48-6P
 1131452-49-7P 1131452-50-0P 1131452-51-1P
 1131452-52-2P 1131452-53-3P 1131452-54-4P
 1131452-55-5P 1131452-56-6P 1131452-57-7P
 1131452-58-8P 1131452-59-9P 1131452-60-2P
 1131452-62-4P 1131452-63-5P 1131452-64-6P
 1131452-65-7P 1131452-66-8P 1131452-67-9P
 1131452-68-0P 1131452-69-1P 1131452-70-4P
 1131452-71-5P 1131452-72-6P 1131452-73-7P
 1131452-74-8P 1131452-75-9P 1131452-76-0P
 1131452-77-1P 1131452-78-2P 1131452-79-3P
 1131452-80-6P 1131452-81-7P 1131452-82-8P
 1131452-83-9P 1131452-84-0P 1131452-85-1P
 1131452-86-2P 1131452-87-3P 1131452-88-4P
 1131452-89-5P 1131452-90-8P 1131452-91-9P
 1131452-92-0P 1131452-93-1P 1131452-94-2P
 1131452-95-3P 1131452-96-4P 1131452-97-5P
 1131452-98-6P 1131452-99-7P 1131453-00-3P
 1131453-01-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of substituted indolyl compds. as 5-HT6 ligands
 useful in the treatment of diseases)


RN 1131452-43-1 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)-
 (CA INDEX NAME)



RN 1131452-44-2 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-4-piperidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 1131452-45-3 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 1131452-46-4 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-47-5 CAPLUS

CN 1H-Indol-4-amine, N-ethyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-48-6 CAPLUS

CN 1H-Indol-4-amine, N-ethyl-1-[(2-chlorophenyl)sulfonyl]-N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-49-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-50-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[[4-(1-methylethyl)phenyl]sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-51-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1-[(4-isopropylphenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-52-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-53-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131452-54-4 CAPLUS
 CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 1131452-55-5 CAPLUS
 CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-4-piperidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 1131452-56-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methyl-4-piperidiny)-
(CA INDEX NAME)



RN 1131452-57-7 CAPLUS


CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-4-piperidiny-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-58-8 CAPLUS


CN 1H-Indol-4-amine, N-methyl-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 1131452-59-9 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)




RN 1131452-60-2 CAPLUS

CN 1H-Indol-4-amine, 1-[(2,5-dimethoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-62-4 CAPLUS


CN 1H-Indol-4-amine, N-methyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-63-5 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-

piperidinyl)- (CA INDEX NAME)




RN 1131452-64-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-65-7 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-66-8 CAPLUS

CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidiny1)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-67-9 CAPLUS

CN 1H-Indol-4-amine, N-methyl-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-68-0 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-69-1 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-70-4 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-71-5 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-72-6 CAPLUS


CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-

methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-73-7 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-fluorophenyl)sulfonyl]-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-74-8 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-75-9 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-N-(1-methyl-4-piperidiny1)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-76-0 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methoxyphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-77-1 CAPLUS

CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-78-2 CAPLUS

CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-79-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-80-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-81-7 CAPLUS


CN 1H-Indol-4-amine, 1-[(4-bromophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-82-8 CAPLUS
 CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-83-9 CAPLUS
 CN 1H-Indol-4-amine, N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-84-0 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-85-1 CAPLUS

CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1131452-86-2 CAPLUS


CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




RN 1131452-87-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-ethyl-4-piperidiny)-
(CA INDEX NAME)



RN 1131452-88-4 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidiny)-
(CA INDEX NAME)




RN 1131452-89-5 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidiny)-1-[(4-fluorophenyl)sulfonyl]-
(CA INDEX NAME)




RN 1131452-90-8 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidiny)-
(CA INDEX NAME)




RN 1131452-91-9 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidiny)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-92-0 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidiny)-1-[(4-methoxyphenyl)sulfonyl]-
(CA INDEX NAME)




RN 1131452-93-1 CAPLUS

CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidiny1)-1-[[4-(1-methylethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131452-94-2 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methylphenyl)sulfonyl]-N-(1-propyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-95-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-propyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131452-96-4 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidiny)-
(CA INDEX NAME)




RN 1131452-97-5 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-(1-propyl-4-piperidiny)-
(CA INDEX NAME)




RN 1131452-98-6 CAPLUS

CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidiny)-
(CA INDEX NAME)




RN 1131452-99-7 CAPLUS

CN 1H-Indol-4-amine, N-(1-propyl-4-piperidiny1)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 1131453-00-3 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-propyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131453-01-4 CAPLUS


CN 1H-Indol-4-amine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-propyl-4-piperidiny1)- (CA INDEX NAME)




IT 1131453-02-5P 1131453-03-6P 1131453-04-7P
 1131453-05-8P 1131453-06-9P 1131453-07-0P
 1131453-11-6P 1131453-12-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of substituted indolyl compds. as 5-HT6 ligands
 useful in the treatment of diseases)
 RN 1131453-02-5 CAPLUS
 CN 1H-Indol-4-amine, N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131453-03-6 CAPLUS
 CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidiny1]- (CA INDEX NAME)




RN 1131453-04-7 CAPLUS
 CN 1H-Indol-4-amine, N-ethyl-N-(1-methyl-4-piperidiny1)- (CA INDEX NAME)




RN 1131453-05-8 CAPLUS
 CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-06-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1H-indol-4-ylmethylamino)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1131453-07-0 CAPLUS
 CN 1H-Indol-4-amine, N-methyl-N-4-piperidinyl- (CA INDEX NAME)




RN 1131453-11-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131453-12-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

37.86

255.12

FILE 'REGISTRY' ENTERED AT 07:30:02 ON 28 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2009 HIGHEST RN 1149431-57-1

DICTIONARY FILE UPDATES: 26 MAY 2009 HIGHEST RN 1149431-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 1131453-03-6

L9 1 1131453-03-6

(1131453-03-6/RN)

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

255.60

FILE 'CAPLUS' ENTERED AT 07:30:12 ON 28 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22

FILE LAST UPDATED: 27 May 2009 (20090527/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

=> s 19

L10 1 L9

=> d bib abs hitstr

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2009:336963 CAPLUS

DN 150:329617

TI Substituted indolyl compounds as 5-HT6 ligands and their preparation, and use in the treatment of diseases

IN Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati, Rama Sastri; Jasti, Venkateswarlu

PA Suven Life Sciences Limited, India

SO PCT Int. Appl., 64pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2009034581	A1	20090319	WO 2008-IN280	20080502
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI IN 2007-CH2030 A 20070911

OS MARPAT 150:329617

GI



AB The invention relates to substituted indolyl compds. of formula I, their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. Compds. of formula I wherein R is H, C1-3 alkyl, and C3-6 cycloalkyl; R1, R2 and R3 are independently H, halo, C1-3 (halo)alkyl, C3-6 cycloalkyl, and C1-3 (halo)alkoxy; R4 is H, C1-3 (halo)alkyl, aryl, aralkyl, C3-6 cycloalkyl and tert-butoxycarbonyl; m is 0 - 4; n and p are independently 0 - 5; are claimed. The invention also relates to a process for the preparation of above said compds., their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. This invention also relates to the intermediates involved therein and process of their preparation. These compds. are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Example compound II was prepared by reductive amination of 1-methylpiperidin-4-one with 4-amino-1-(2-bromophenylsulfonyl)-1H-indole. All the invention compds. were evaluated for their 5-HT6 modulatory activity. From the assay, it was determined that compound II exhibited Ki value of 17.9 nM.


IT 1131453-03-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted indolyl compds. as 5-HT6 ligands useful in the treatment of diseases)


RN 1131453-03-6 CAPLUS

CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 9 10 17
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

=> s 11 ful
 FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 9156 TO ITERATE

100.0% PROCESSED 9156 ITERATIONS 30 ANSWERS
 SEARCH TIME: 00.00.01

L3 30 SEA SSS FUL L1

=> fil caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 187.80 188.52

FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family
of databases will soon be updated to include new citing references
information. This enhancement may impact record import into
database management software. For additional information, refer
to NEWS 22.

=> s l3

L4 2 L3




=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly
selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf;
Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A
antagonists is reported herein. Selectivity for the serotonin 5-HT2A
receptor was optimized, decreasing the affinity of these antagonists
toward the adrenergic $\alpha 1$ and dopaminergic D2 receptors, and especially to
the 5-HT2C receptor. A series of corresponding 7-substituted indoles is
described for the first time as serotonergic ligands. The enantiomer
R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-
yl}ethanol was identified to have superior affinity for the serotonergic
5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic
D2- [IC50 = 2300 nM], adrenergic $\alpha 1$ - [IC50 = 1000 nM] and 5-HT2C
receptors [IC50 = 490 nM].
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		
OS	MARPAT 143:286283				
GI					




AB Title compds. I [A = (R2)_n; B = (X)_m; X = H, halo, CN, etc.; Y = CHR₂CHR₂, CR₂=CR₂; Q = O, OH, NH, etc.; R1 = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R2 = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethyldindole III. Compds. I are claimed to be 5-HT_{2a} antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 9 10 17
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

=> s l1 ful
 FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 9156 TO ITERATE

100.0% PROCESSED 9156 ITERATIONS 30 ANSWERS
 SEARCH TIME: 00.00.01

L3 30 SEA SSS FUL L1

=> fil caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 187.80 188.52

FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family
of databases will soon be updated to include new citing references
information. This enhancement may impact record import into
database management software. For additional information, refer
to NEWS 22.

=> s l3

L4 2 L3




=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly
selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf;
Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A
antagonists is reported herein. Selectivity for the serotonin 5-HT2A
receptor was optimized, decreasing the affinity of these antagonists
toward the adrenergic $\alpha 1$ and dopaminergic D2 receptors, and especially to
the 5-HT2C receptor. A series of corresponding 7-substituted indoles is
described for the first time as serotonergic ligands. The enantiomer
R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-
yl}ethanol was identified to have superior affinity for the serotonergic
5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic
D2- [IC50 = 2300 nM], adrenergic $\alpha 1$ - [IC50 = 1000 nM] and 5-HT2C
receptors [IC50 = 490 nM].
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		
OS	MARPAT 143:286283				
GI					



AB Title compds. I [A = (R₂)_n; B = (X)_m; X = H, halo, CN, etc.; Y = CHR₂CHR₂, CR₂=CR₂; Q = O, OH, NH, etc.; R₁ = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R₂ = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethyldindole III. Compds. I are claimed to be 5-HT2a antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT